We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fecal Calprotectin Predicts Complete Mucosal Healing in UC

By LabMedica International staff writers
Posted on 13 Nov 2017
Print article
Image: The rapid Quantum Blue Fecal Calprotectin lateral flow test (Photo courtesy of Bühlmann Laboratories).
Image: The rapid Quantum Blue Fecal Calprotectin lateral flow test (Photo courtesy of Bühlmann Laboratories).
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by a disease course involving relapses and remissions. Historically, clinical remission was the major treatment target for patients with UC.

The use of repeated endoscopy to verify mucosal healing (MH) is invasive, inconvenient, and expensive, and may present a risk of significant complications such as colonic perforation. Therefore, noninvasive surrogate markers indicating endoscopic healing have been investigated to replace the repeated endoscopic procedures.

Scientists at the University of Ulsan College of Medicine (Seoul, Republic of Korea) collected 181 fecal samples from 181 consecutive UC patients between April 2015 and September 2016. Collected data included birth date, sex, date of UC diagnosis, family history of IBD, smoking status, maximum disease extent, and medications. The laboratory test results, partial Mayo Score (pMS), and colonoscopic imaging findings at Fecal Calprotectin (FC) level measurement were retrospectively reviewed.

FC levels were measured using the Quantum Blue Calprotectin rapid test (Bühlmann Laboratories AG, Schönenbuch, Switzerland), and high-range kit measuring 100–1,800 mg/kg was used. The following laboratory parameters were recorded at the time of FC level measurement: complete blood cell count on the XE-2100 (Sysmex Corporation, Kobe, Japan), including white blood cell count, hemoglobin level, hematocrit value, and platelet count; erythrocyte sedimentation rate (ESR); and serum chemistry values on the Cobas 8000 modular analyzer (Roche Diagnostics, Basel, Switzerland), and the AU5800 (Beckman Coulter, Brea, CA, USA), including C-reactive protein (CRP) and albumin levels.

The investigators found that among the biochemical markers, FC levels exhibited significant correlations with the CRP and serum albumin. The other laboratory values including white blood cell count, hematocrit values, platelet and ESR exhibited weaker correlations with the FC levels, as compared to both the CRP and serum albumin levels. The FC cut-off level of 187.0 mg/kg indicated complete mucosal healing with a sensitivity and specificity of 0.857 and 0.891, respectively.

The authors concluded that the FC level is significantly correlated with the clinical disease activity index, endoscopic indices, and serum inflammatory biomarkers in a Korean UC cohort. FC is highly predictive of complete mucosal healing in UC. UC endoscopic index of severity (UCEIS) exhibits a stronger correlation with the FC level; as compared to the Mayo endoscopic subscore (MES). Thus, FC could be used as a reliable noninvasive indicator for evaluating disease activity and mucosal healing in UC. The study was published on October 23, 2017, in the journal BMC Gastroenterology.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more